Filtered library · Archetype
Earnings inflection · 164 dossiers
Dossiers classified as Earnings inflection — 164 names, each with its thesis, invalidation trigger and catalyst calendar.
All dossiersOSCR
Oscar Health, Inc.
Margin-recovery re-rate has carried the ACA pure-play leader to new highs, clearing the $30.38 prior 52-wk high on the +11% July 1 break with managed-care breadth (CNC/MOH/AGL) accelerating. But at $30.54 it trades ~28% above the $23.8…
IRDM
Iridium Communications Inc
Narrative-momentum thesis is closed: Rocket Lab agreed 2026-06-29 to acquire Iridium for ~$54/share ($27 cash + a calculated ratio of RKLB stock), EV ~$8B. IRDM now trades as merger-arb spread to ~$54 plus embedded RKLB beta not on NTN…
OKLO
freshOklo Inc.
Momentum leg is dead: OKLO sliced its 52-week floor at $44.16 on 2026-07-16 to $41.03 (-79% from the Oct-2025 $193.84 peak, -28% in a month) and capital is rotating to peers. Everything now hangs on one dated binary Groves reactor…
SMR
NuScale Power Corporation
Sovereign-capital binary: the KORUS $200B package lists nuclear among strategic sectors and reportedly eyes a NuScale reference plant, but the leg is undated and unsigned. June's ~$14 pop fully round-tripped; shares press the $8.85 52-week…
TSLA
freshTesla, Inc.
Optimus/Robotaxi leg is expanding geographically (Miami + Texas fleet, BofA $460) but the tape broke down anyway the Musk-complex bid inverted as SPCX retreats from post-IPO highs, ARKK bleeds assets, and Chinese brands took a record 16.5%…
CMPS
COMPASS Pathways Plc
COMP006 Phase 3 in TRD read out positive on 2026-07-07 (26-week durability, 2027 launch reiterated), completing the pivotal package alongside COMP005 and triggering a same-week analyst upgrade cluster; the psychedelic-mental-health…
MIRM
Mirum Pharmaceuticals, Inc.
Rare-disease platform re-rating on stacked de-risking: zilurgisertib FOP PDUFA set for 2026-09-26 after a 99.9% HO-lesion reduction, brelovitug HDV Phase 3 topline due 2H26, and Q1 sales +43% YoY with 2026 guide lifted to $660–680M. Six…
PSNL
freshPersonalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus…
ABCL
AbCellera Biologics Inc.
Busted-platform turnaround re-accelerated: broke the $6.79 ceiling to a new 52-wk high $8.44 off the June $5.09 base, now retesting the breakout shelf near $6.88. Jazz TCE deal validated the discovery engine and Benchmark's 2026-07-07 $11…
AGIO
Agios Pharmaceuticals, Inc.
Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (Jun 15) + FDA Priority Review acceptance (Jul 7, ~+15%) + same-day PT cluster to $46. The binary payoff is the ~Nov 1 2026 PDUFA; the acceptance pop is already digested and…
ALMS
Alumis Inc.
Best-in-class oral TYK2 narrative accelerating after Phase 3 psoriasis wins (PASI 100 ~40% at Week 24); the Q3 2026 LUMUS Phase 2b lupus topline is the binary that either re-rates the platform into a multi-billion indication or caps it as…
AVTX
Avalo Therapeutics, Inc.
Post-LOTUS de-risked anti–IL-1β (abdakibart) story: the May 5 Phase 2 HS win (HiSCR75 ~42% vs 26% placebo) already re-rated the stock ~4x, and it is now fully funded into 2029, Russell-included, with sell-side initiating at $35–$38. But…
CCC
freshCCC Intelligent Solutions Holdings Inc.
Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is…
CGEM
Cullinan Therapeutics, Inc.
Re-rated ~3x off the $5.68 low as the CD19 T-cell-engager-in-autoimmune narrative accelerated; CLN-978 remissions in lupus/RA (Immunology Day 2026-06-10) drove it. Now bull-flagging under the $19.43 high with no hard-dated catalyst until…
DNTH
Dianthus Therapeutics, Inc.
Single-asset complement biotech (claseprubart/DNTH103) broke out to a new 52-week high near $102 in July, reclaiming and extending well above the $81 March offering shelf as the Sanofi same-mechanism CIDP fear faded and analyst PTs…
DRTS
Alpha Tau Medical Ltd.
Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +…
DSGN
Design Therapeutics, Inc.
Post-print collapse fully reversed: DSGN re-rated +40% in June to $15.19 (2026-07-10), reclaiming the $14.37 data-day high and pressing toward the $17.25 52-week high as the FA gene-therapy theme accelerated and the pipeline broadened…
DYN
freshDyne Therapeutics, Inc.
Neuromuscular RNA-conjugate name re-rating near its 52-week high ($25) on a de-risked path: z-rostudirsen DMD exon-51 BLA submitted 2026-05-26 with Priority Review requested. The FDA filing/Priority-Review decision (~late July) and the…
ELF
freshe.l.f. Beauty, Inc.
Sell-side flipped from cutting to marking up in ten days five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative…
ELVN
Enliven Therapeutics, Inc.
Post-EHA, de-risked best-in-class oral BCR::ABL1 asset (ELVN-001) heading to Phase 3 ENABLE-2 (2H 2026), over-funded at >$800M pro-forma after the $37.50 raise. The June 11 catalyst is spent, yet the sell-side is re-rating hard (PTs…
GHRS
freshGH Research PLC
Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next…
GLUE
Monte Rosa Therapeutics, Inc.
Molecular-glue degrader story accelerating: Novartis-validated platform ($150M upfront, $2.1B milestones) plus a wholly-owned NLRP3/NEK7 asset (MRT-8102) that cut CRP 85% in Jan-2026 interim data. Guggenheim named GLUE an H2 top pick (PT…
LQDA
freshLiquidia Corporation
YUTREPIA commercial ramp plus S&P SmallCap 600 inclusion and a SCOTUS-de-risked '327 overhang pushed LQDA to new highs near $80 — but the coiled asymmetry is spent: price now sits above the ~$69 consensus target with insiders selling into…
MAZE
Maze Therapeutics, Inc.
APOL1 kidney precision-medicine story re-accelerating post-HORIZON: Phase 2 (Mar-25-2026) gave first broad-AMKD proof-of-concept (35.6% proteinuria cut, 61.8% in FSGS), stock reclaimed the April $23.50 raise, and a second oral asset…
MESO
freshMesoblast Limited
Platform inflection: Ryoncil delivered $115M first-year revenue above its $110-120M guide, and Mesoblast is stacking regulatory optionality a modular BLA filed for rexlemestrocel-L in LVAD heart failure plus a fully-enrolled Phase 3…
MGTX
freshMeiraGTx Holdings plc
The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but the…
NGNE
Neurogene Inc.
NGN-401 Rett-syndrome gene-therapy narrative re-accelerated on the 2026-06-29 low-dose data update, strong enough to place a $125M raise at $30 the next day. Data and financing are now both out, so the next binary is FDA…
NKTR
freshNektar Therapeutics
M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh…
NRIX
Nurix Therapeutics, Inc.
Bexobrutideg BTK-degrader franchise is re-rating: six firms raised targets to $32-40 on 2026-07-10, one day after a 44% Q2 revenue miss the sell-side dismissed as collaboration-revenue noise. EHA 2026 CLL durability is the driver, but the…
ORKA
freshOruka Therapeutics, Inc.
Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B…
PESI
freshPerma-Fix Environmental Services, Inc.
Nuclear-cleanup inflection accelerating: Hanford vit-plant hot commissioning plus DOE grouting awards (200W ~$216M/yr, 200E ~$75M/yr) repricing a ~$62M-revenue cleanup contractor as a multi-bagger. Shares broke to a 52-week high (+13.6%…
PGEN
Precigen, Inc.
PAPZIMEOS launch inflection accelerating the first and only FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026 (a beat), with cash-flow breakeven guided by year-end and orphan exclusivity to 2032; the ~Aug 10 Q2 print…
PTGX
Protagonist Therapeutics, Inc.
De-risked dual-royalty inflection: icotrokinra (oral IL-23, J&J) already FDA-approved and paying 6–10% royalties, rusfertide (PV, Takeda) with a 76.9% VERIFY Phase 3 heading into a Q3 2026 PDUFA. Stock tripled off $49 to an all-time high;…
PVLA
Palvella Therapeutics, Inc.
First-ever-approval-for-microcystic-lymphatic-malformations narrative accelerating and de-risked: SELVA hit its endpoint (Feb 24, 2026), FDA granted rolling NDA review, first module filed June 29, 2026. But no binary inside 30 days NDA…
PYPL
freshPayPal Holdings, Inc.
Narrative flipped from broken-fintech fade to live takeover situation: Stripe/Advent bid $60.50 (>$53B) on 2026-07-15 sent PYPL +17.2%, its best day ever, to $56.56. Board called it inadequate (Reuters 2026-07-17), meeting ~2026-07-20. ~7%…
RAPP
freshRapport Therapeutics, Inc.
RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.…
RIVN
freshRivian Automotive, Inc.
Q2 deliveries beat and the full-year output forecast was RAISED (2026-07-15, ~5% rally), giving the July moving-average reclaim a fundamental leg. But the death cross from ~2026-05-27 is uncured and sell-side skew is still…
RLAY
freshRelay Therapeutics, Inc.
Post-binary re-rating extended by an analyst-coverage land grab: JP Morgan initiated Overweight $28 (2026-07-08) and Canaccord Buy $29 (2026-07-16) on top of the June upgrade wave, carrying RLAY to a new 52-week high of $20.19 (~450% TTM).…
RLYB
freshRallybio Corporation
Corrected cash math changes the read: the $50.0M Candid break fee received 2026-05-04 landed after the 3/31 balance sheet, so ~$97M gross cash sits against 5.30M shares (~$18.3/sh) versus a $16.42 quote. Buyer gets the cash distribution…
RMAX
freshRe/Max Holdings, Inc.
Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80…
RPAY
freshRepay Holdings Corporation
The takeout fight re-fired: Forager returned 2026-06-29 with $5.25 cash 9% above the $4.80 the board killed in May and was rejected again 2026-07-13, the same day the board seated a Parthenon-affiliated director under a cooperation…
SLDB
Solid Biosciences Inc.
Next-gen DMD gene therapy filling the vacuum from Sarepta Elevidys's safety collapse; SGT-003 clean across 40 dosed (no DILI/TMA/myocarditis, May 4 2026 cutoff) with ~110% microdystrophin expression. +172% off the low to $10.42 the…
SNDX
Syndax Pharmaceuticals, Inc.
Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance…
TENX
Tenax Therapeutics, Inc.
Positive Phase 3 LEVEL topline in PH-HFpEF (early-June 2026) triggered a clustered analyst re-rate (Piper $50, Guggenheim $40, Cantor $35, Chardan initiates $27); oral levosimendan de-risked in an indication with no approved therapy. ESC…
TRIP
TripAdvisor, Inc.
Activist breakup/sale special situation past its board-control catalyst: Starboard seated its 4th designee at the June 29 annual meeting and sale talk is intensifying, with the $700M TheFork-to-Amex cash sale proving the board will…
TRVI
freshTrevi Therapeutics, Inc.
Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional…
ZVRA
Zevra Therapeutics, Inc.
MIPLYFFA's patent cliff was pushed to 2041 (Orange Book listing 2026-06-08), and three weeks on the re-rating has held ZVRA sits ~$13.80, near its $14.58 52-week high, rather than fading. But the discrete catalyst is behind the tape; the…
AAPL
freshApple Inc.
Apple retook the world's-largest-company title from Nvidia on 2026-07-17 after a $1.45T two-month swing, powered by rotation out of AI semis plus a $30B Broadcom custom-silicon deal and reported AI-chip M&A hunting. The re-rate is now…
ABEO
freshAbeona Therapeutics Inc.
ZEVASKYN commercial ramp inflecting: Q1 revenue of $8.7M nearly doubled the ~$4.57M consensus and management floated monthly profitability by June. The mid-August Q2 print (~2026-08-12) is the binary that confirms or breaks the…
ABVX
Abivax SA
Obefazimod's positive Phase 3 UC maintenance data (June 29) completed a de-risked oral pivotal package, but the binary has already fired: a +36% gap to ~$130 plus an $800M raise at $125 mark this as a MATURING, sell-side-caught story, not…
ACB
Aurora Cannabis Inc.
Sentiment-beta proxy on the U.S. cannabis-reschedule trade, but a Canadian LP with no U.S. THC ops the structural laggard. Broke to a fresh $2.63 52-week low; FY2027 guided as a "reset year" with revenue declining on a ~30% Canadian…
ACDC
ProFrac Holding Corp.
the headlines that drove it to $8.15 in June no longer bid it. A glut overhang broke the beta into a loss-making frac core.
AKBA
Akebia Therapeutics, Inc.
USRC-sponsored VOICE outcomes trial (2026-06-30) stopped early for success Vafseo cut dialysis hospitalizations vs ESAs with neutral mortality, a hard-data adoption catalyst for this ~$1.40 renal micro-cap. But price sits near its 52-week…
ALHC
Alignment Healthcare, Inc.
Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares…
ALOT
AstroNova, Inc.
AstroNova is a closed narrative: Arcline's $29.00 all-cash take-private (announced 2026-06-17, ~$272M, Q3-2026 close) hard-caps the stock. The 200%+ pop was a one-time buyout gap, not an accelerating story what remains is a thin merger-arb…
ANAB
AnaptysBio, Inc.
Pure-play Jemperli/imsidolimab royalty stub since the April spin-off; the entire equity now hinges on the 2026-07-14–17 Delaware Chancery trial on royalty reversion and rate preservation now 1–3 trading days out. A binary legal verdict,…
ANRO
Alto Neuroscience Inc.
Precision-psychiatry re-rate that has already run ~10x off a $2.50 low to near its $28.44 high; funded through 2029 on the March $120M PIPE, but every binary readout (ALTO-300, ALTO-100, ALTO-207 in TRD) sits in 2027 the tape near highs is…
APGE
Apogee Therapeutics, Inc.
AbbVie's confirmed $135.11 all-cash takeout (announced 2026-06-23, ~$10.9B, ~49% premium to the $90.38 pre-bid close) caps the stock at the bid and extinguished the IL-13 momentum leg; the downgrade cluster reset ratings to Hold at the…
ATAI
AtaiBeckley Inc.
Between-catalyst psychedelic leader jolted by a 2026-07-06 volume spike on an unconfirmed M&A-blog takeout rumor, stacked on Russell 2000/3000 inclusion (effective 2026-06-29) and a Canaccord PT bump to $17 (2026-07-07). The one hard…
AVNS
Avanos Medical, Inc.
All-cash $25.00 take-private of Avanos by American Industrial Partners is now a near-closed pin: all regulatory approvals obtained 2026-07-02, leaving only the 2026-07-22 shareholder vote before an expected close by 2026-07-27. The spread…
BAK
Braskem S.A.
Distress jumped from the Idesa JV to the parent: ~2026-06-29 Braskem S.A. won a 60-day creditor standstill, Fitch cut to C and S&P to D (default), and JPMorgan capitulated to Neutral (2026-06-30) as creditors rejected management's plan and…
BBNX
Beta Bionics, Inc.
Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the…
BCAX
freshBicara Therapeutics Inc.
Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,…
BHVN
Biohaven Ltd.
Spec-biotech de-rate reversal on opakalim epilepsy data, now >110% off the $7.48 low to ~$16; RISE3 enrollment complete and shares shrugged off a BofA Underperform ($11), but the value-driving topline is unscheduled 2H-26 and a dilution…
BIOA
BioAge Labs, Inc.
Left-for-dead pivot re-rated ~6x off $4: oral NLRP3 inhibitor BGE-102 reframes BIOA as a "statin-for-inflammation" CV play after median 86% hsCRP cuts in Phase 1. QUELL-CV Phase 2 topline (2H 2026) is the binary. Now grinding fresh 52-week…
BOLD
Boundless Bio, Inc.
Post-2026-06-23 reverse merger into Serapha Bio, this stopped being an oncology stock. The tradable object is a defined ~$44–48M pre-close cash dividend plus a ~3.7% stub in the AATD base-editing NewCo (future ticker AATD), not an…
BTGO
BitGo Holdings, Inc.
Broken IPO (~$5.13 vs $18 Jan listing) that just printed a fresh all-time low at $4.67 as the 2026-06-17 buyback bounce faded rolling into a 2026-07-21 lockup unlock (~10 days out), a new 15% layoff, and a fresh IPO-period securities class…
BWIN
freshThe Baldwin Insurance Group, Inc.
Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,…
CADL
Candel Therapeutics, Inc.
CAN-2409 narrative re-armed on the 2026-06-30 AURORA Phase 3 launch in post-ICI NSCLC a second pivotal program in a far larger indication plus an ex-AstraZeneca lung CCO hire; the stock cleared the old $9.27 high to an $11.36 peak, then…
CCRN
Cross Country Healthcare, Inc.
Deal-pinned cash merger-arb, not a momentum trade. Knox Lane taking CCRN private at $13.25 cash; HSR cleared 2026-06-22 for both the merger and the locums sale, leaving only the 2026-07-16 shareholder vote. ~0.3% capped upside vs ~25%…
CCXI
freshChurchill Capital Corp XI
Humanoid-robotics de-SPAC: Churchill XI merges with Agility Robotics (~$2.5B, Nvidia/Amazon-backed, re-lists as AGLT). Theme intact, but the tape is an RSI-98 filing-driven blow-off that has since gone quiet with no dated catalyst until…
CDNA
freshCareDx, Inc.
Multi-year Medicare overhang lifted: finalized MolDX LCD (2026-07-16, effective 2026-08-30) affirms surveillance dd-cfDNA coverage for kidney/heart/lung transplants, driving a ~+28% re-rate to a fresh 52-week high near $40. Structurally…
CGC
Canopy Growth Corporation
Federal cannabis rescheduling is a live but dissipating binary: the DEA adult-use Schedule III hearing (opened 2026-06-29) closes 2026-07-15 with written briefs and no verdict, and the ALJ recommendation is undated afterward all seven…
CLDX
freshCelldex Therapeutics, Inc.
Single-asset immunology binary: barzolvolimab (anti-KIT mast-cell depleter) has both Phase 3 CSU trials fully enrolled six months early, with topline Q4 2026 the coin-flip. Stock ~$35 vs $53 median target, but the tape is range-bound in…
CNMD
freshCONMED Corporation
Broken-medtech value name flipped to a live takeover play: the board is weighing strategic alternatives including a sale after PE interest, gapping the stock from the mid-$30s to ~$42 (+10.5% after-hours, ~2026-07-11). M&A optionality is…
CNTA
Centessa Pharmaceuticals plc
Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are…
CODI
Compass Diversified
Post-fraud recovery (+~115% off the $4.58 low) has stalled: a 2026-07-01 +9% pop to $11.57 faded back under the 50-day (~$11.14) to ~$10.08 by 2026-07-08 on volume 53% below average. Only live optionality is the delayed Management Services…
CORT
Corcept Therapeutics Incorporated
Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…
CRNX
Crinetics Pharmaceuticals, Inc.
Momentum story is dead it crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to $83.53 (+99%) and now trade as a merger-arb spread capped at $85, with ~$40 of air below on a deal-break. No…
CRTO
Criteo S.A.
Deal-or-no-deal special situation: the 2026-07-06 Vista/Quinti take-private bid >$50 against a ~$23 tape implies the market prices only low-teens completion odds, earned by Criteo's serial failed-sale history. The momentum pop already…
CRVS
Corvus Pharmaceuticals, Inc.
Clean Phase 1 AD binary resolved 2026-05-14 (sold off 28%), but since the ~$10 late-May low shares have re-rated ~55% to $15.67 (2026-07-10), reclaiming the 50-day as the oncology-immunology theme firms. The recovery runs into a summer…
EPC
Edgewell Personal Care Company
A rejected $30/share Yellow Wood bid (2026-06-22) flips EPC from dead-tape value-trap to a live take-private special situation the board refused outright as too low and shares gapped +18% to new highs near $27. The leg being bought is M&A…
ERAS
Erasca, Inc.
Best-in-class pan-RAS efficacy (ERAS-0015: 62–75% NSCLC ORR) already discounted through a ~48% post-print crash; stock round-tripped from ~$10 to ~$16 into overhead supply while the RevMed '225 patent fight and a securities class-action…
ESPR
Esperion Therapeutics, Inc.
ARCHIMED take-private cleared its last binary: the 2026-07-08 vote adopted the deal (135.3M for vs 22.8M against), and with HSR and German antitrust already done only the mechanical Q3 close and Nasdaq delisting remain. Stock is pinned at…
EVH
freshEvolent Health, Inc
The late-June retail bounce has fully unwound EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which is…
FOUR
freshShift4 Payments, Inc.
Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary…
FWRD
Forward Air Corporation
Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited…
GBTG
Global Business Travel Group, Inc.
Signed $9.50/share cash take-private by Long Lake (~$6.3B; General Catalyst + Alpha Wave backed); 69% of shares locked via voting agreements, close guided 2H 2026. Stock pinned ~$9.36 pure merger-arb with ~1.5% capped upside vs ~37%…
GCO
Genesco Inc.
The operating turnaround is real but priced, and its one asymmetric leg the activist proxy fight lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…
GERN
Geron Corporation
Post-launch broken-momentum hematology name: RYTELO 2L lower-risk MDS ramp is real but decelerating (Q1 2026 $51.8M net rev, +31% YoY) while the stock sits near its $1.04 52-week low, below every major MA. The only live re-rate is the…
GSHD
freshGoosehead Insurance, Inc.
Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55) against a stock still at $54.28 and -49% YoY. The 2026-07-22 Q2 print is the binary that decides…
HOV
Hovnanian Enterprises, Inc. Class A
ROAD-to-Housing relief pop has fully round-tripped: HOV ran to $147.55 (06-26) then bled to the low $120s as the bill became law WITHOUT a signature on 07-11 the bull catalyst arrived and the stock fell. Sell-the-news is complete; two…
HPP
Hudson Pacific Properties, Inc.
West Coast office/studio REIT that nearly tripled off the April $5.51 low; operating recovery is real but the move has matured into a split $12–$16 analyst cluster with B of A now at Underperform. The trade is now a binary ~$566M CMBS…
HROW
Harrow, Inc.
Commercial ophthalmology special-situation trading on one number: does the guided H2 ramp print. June–July portfolio launches (VERKAZIA, BYOOVIZ) keep sentiment alive, but the binary is the ~Aug 10 Q2 report $71–81M guide vs $44.2M Q1. A…
IDYA
IDEAYA Biosciences, Inc.
Precision-oncology name digesting a $300M raise at $27.00 (priced 2026-06-09); analysts cut targets 2026-07-07 (RBC $48, Truist $63) while staying bullish. Darovasertib uveal-melanoma registrational path is the embedded option, but the…
IHRT
iHeartMedia, Inc.
M&A special-sit stays the dormant leg SiriusXM talks stalled over the divestiture/antitrust impasse and unrevived but the $6.56 April spike stabilized near $4.05 instead of bleeding out, and a fundamental H2 story (2026 midterm…
IMRX
Immuneering Corporation
Post-ASCO sell-the-news biotech: atebimetinib's 17.3-month first-line pancreatic OS is real but single-arm, and the Phase 3 OS binary is ~2 years out (mid-2028). Near-term is a coverage and base-building story with no dated OS catalyst…
INBX
Inhibrx Biosciences, Inc.
Near-term regulatory binary resolved favorably FDA accepted the ozekibart chondrosarcoma BLA on 2026-06-15 (PDUFA 2027-04-14) but that docketed the defining decision ~9 months out, dropping the name into an extended catalyst vacuum.…
IRWD
freshIronwood Pharmaceuticals, Inc.
Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…
JBIO
freshJade Biosciences, Inc.
Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put…
JBLU
freshJetBlue Airways Corporation
Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B…
JOBY
freshJoby Aviation, Inc.
eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment…
KALV
freshKalVista Pharmaceuticals, Inc.
Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…
KNX
freshKnight-Swift Transportation Holdings Inc.
Freight cycle has physically inflected tender rejections 17.2%, spot above contract for the first time since 2021 but the tape stalled at ~$76.68 versus a $86.63 average target. The whole trade now compresses into the 2026-07-22 Q2 print…
KOD
freshKodiak Sciences Inc
ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary either…
KURA
Kura Oncology, Inc.
Ziftomenib/Komzifti approval (2025-11-13) already de-risked the story; the Street's $24-28 targets underwrite a frontline-AML expansion gated to a 2028 Phase 3. Stock consolidates near its $12.49 52-week high on a slow launch ($5.8M Q1)…
LPRO
freshOpen Lending Corporation
All-cash takeout has closed the story. ANV Group's $3.15 tender for Open Lending went live 2026-06-29 with a 2026-07-27 initial expiry; the equity is pinned to the deal price with no momentum leg only a thin arb spread against…
LRMR
Larimar Therapeutics, Inc.
Single-asset FA binary: nomlabofusp rolling BLA underway for accelerated approval on a novel frataxin surrogate, Breakthrough-designated and FDA-aligned but shares sit near 52-week lows after a -15% sell-the-news on the 2026-06-29 filing,…
MBX
freshMBX Biosciences, Inc.
Once-weekly canvuparatide's 1-yr Phase 2 durability (57% responders, 12 Jun) plus a cleared End-of-Phase-2 FDA path drove a +580% YTD re-rating into all-time highs. With the data catalyst spent, no dated binary inside 30 days, and an…
MGM
freshMGM RESORTS INTERNATIONAL
Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low so the trade is now a bump handicap, not a growth story. At ~$46.91…
MMYT
MakeMyTrip Limited
India-OTA recovery bounce, not a fresh breakout: MMYT is +79% off the $32.67 low and just reclaimed the 200-day (~$55) after HSBC's 2026-07-02 Buy/$70 initiation but a MATURING travel theme runs straight into a binary Q1 FY2027 print…
MRNA
Moderna, Inc.
Flu-vaccine approval story confirmed by an early-July sell-side PT cluster-raise (Piper $77, RBC $45, MS $39, BofA $34→$38), but the clean +30% momentum leg already ran into the June 18 9-0 advisory vote. The Aug 5 mRNA-1010 PDUFA is now…
MXL
freshMaxLinear, Inc.
AI optical/interconnect re-rating is intact PTs $105–125 (Stifel/Northland/Benchmark, 2026-06-25) versus a stock that ran ~$70→~$96.60 into late June but the name now sits ~5 days from a binary Q2 FY26 print (~2026-07-23), retail coverage…
NUVL
Nuvalent, Inc.
Precision-oncology momentum story resolved into an all-cash takeout: GSK's tender at $124/share (commenced 2026-06-24) pins NUVL to the deal price. It is now a merger-arb spread, not a narrative to ride every June downgrade reset its price…
NVCR
freshNovoCure Limited
TRIDENT's OS miss (2026-06-18) killed the re-rating leg the 2026 markup was built on; JPM's 2026-07-13 reinstatement at Neutral/$17 confirms sell-side capitulating toward the ~$15-16 tape. A +12% YoY, loss-making single-asset device name…
ODD
ODDITY Tech Ltd.
Broken DTC-beauty flywheel: IL MAKIAGE's ad-acquisition engine seized on a CPA blowout, Q1 first orders -50%, stock crashed $77→$9.25. The ~$18 bounce sits above nearly every Street PT ($8–$12) into a Q2 print (~mid-Aug) still guided…
OGN
freshOrganon & Co.
Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…
OLPX
freshOlaplex Holdings, Inc.
Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…
OMER
freshOmeros Corporation
Post-CHMP-rejection repair, not a new leg: shares have clawed back from the 2026-06-26 gap low of $8.67 to roughly $9.69 on the J1289 J-code going live 2026-07-01. The 2026-08-13 Q2 print is the whole trade consensus ~$11.6M net sales…
ORIC
freshOric Pharmaceuticals, Inc.
mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is…
PAYO
Payoneer Global Inc.
Merger-arb is the entire story now: Nuvei signed a definitive all-cash deal at $7.40/share (announced June 15), taking PAYO private with close pushed to mid-2027. The narrative re-rate is spent ~4% spread left to the deal price against…
PI
freshImpinj, Inc.
Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS…
PLAY
Dave & Buster's Entertainment, Inc.
The 2026-06-15 binary resolved against the bulls comps -5.4%, revenue -1.5% YoY to $559.2M, EPS $0.16 vs ~$0.60 consensus and the short-covering squeeze round-tripped to ~$11.30. No catalyst until the ~September Q2 comp print tests the…
PLSE
freshPulse Biosciences, Inc
Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant redemption cleared the last dilution overhang, but the de-risking AFib endpoints are 2027…
PLTK
freshPlaytika Holding Corp.
Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…
QDEL
freshQuidelOrtho Corporation
Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture. Sell-side chased it up (Citi $13→$18). The Aug 4 Q2 print is the binary, and a shrinking base…
QURE
freshuniQure N.V.
FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on…
RAMP
freshLiveRamp Holdings, Inc.
Merger-arb stub, not a momentum vehicle: the Publicis $38.50 all-cash deal now has a dated shareholder vote (2026-08-17, 66⅔% threshold) and HSR filed 2026-06-11. At ~$37.82 the remaining spread is ~1.8% into a year-end close, against…
RARE
Ultragenyx Pharmaceutical Inc.
Post-setrusumab-failure reset is now a cleaner two-shot gene-therapy story: DTX401 (GSD Ia) PDUFA ~Aug 23 and UX111 (Sanfilippo A) PDUFA ~Sep 19 are paired binaries, with Angelman GTX-102 Phase 3 topline due H2 2026. Stock ran ~50% into…
RBLX
freshRoblox Corporation
Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary it needs a DAU inflection…
RCKT
Rocket Pharmaceuticals, Inc.
Post-crash gene-therapy rebuild: first commercial approval (KRESLADI/LAD-I) plus a non-dilutive $180M PRV sale (closed 2026-06-12) fund it into Q2 2028, but the real re-rate is the undated H2 2026 RP-A501 Danon update a binary on a program…
REAX
freshThe Real Brokerage, Inc.
Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the $880M RE/MAX deal spooked investors on dilution. The read is now a binary consolidation bet, not…
RLMD
freshRelmada Therapeutics, Inc.
The oncology-pivot re-rate (0.55 to 8.00 in twelve months) has stalled: RLMD lost 10.5% on 2026-07-16 and another 4.0% on 2026-07-17 to $5.24, unwinding the Russell-inclusion bid with no dated NDV-01 catalyst before end-2026. Story intact,…
RPD
Rapid7, Inc.
Growth is gone Q1 2026 revenue -0.3% YoY and Q2 ARR guided down to ~$820M so the only live leg is a take-private: Jana at ~10.3% forced a review and Goldman/JPMorgan are shopping RPD to Advent, Bain. A cheap-FCF LBO target holding above a…
RZLT
freshRezolute, Inc.
Post-interim re-rating has fully decayed: $4.61 on 2026-07-17 vs the $5.14 late-June high, with no dated event between here and the upLIFT full topline in 2H-2026. A binary rare-disease name in its dead zone the 6/8 responder signal is…
SANA
Sana Biotechnology, Inc.
Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the…
SG
freshSweetgreen, Inc.
Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with…
SMMT
freshSummit Therapeutics Inc.
Single-asset ivonescimab binary sitting $1.26 — above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…
SPRY
ARS Pharmaceuticals, Inc.
The single event the name was priced around a July no-prior-auth formulary add for neffy came and went with no coverage win (2026-06-25 update). ARS pivoted to opex cuts ($248M guide) to defend 2027 breakeven as the stock sank and Leerink…
STAA
freshSTAAR Surgical Company
China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the…
STM
freshSTMicroelectronics N.V.
The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA…
STRO
freshSutro Biopharma, Inc.
Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…
SYNA
freshSynaptics Incorporated
All-stock takeout capped the story and the acquirer de-rated: ON's ~19% announcement drop and slide to $87.37 cut the 1.350-ratio implied value from ~$160 to ~$118, with SYNA at $114.05. What's left is a 3.4% gross spread to a mid-2027…
TBRG
freshTruBridge, Inc.
Terminated, not traded: the IKS Health merger closed 2026-07-09 at $26.25/share cash after the 2026-07-07 vote passed 11.31M for / 8,818 against. Shares were cashed out and delisted from Nasdaq. No tradable equity remains; the ticker is a…
TECH
freshBio-Techne Corp
Closed merger-arb: shares pinned just under Merck KGaA's $73 all-cash bid (06-25, $11.3B EV, expected close late-2026/early-2027). The full sell-side has folded targets to $73 (RBC 07-09 the latest). No narrative leg left only thin spread…
TLRY
freshTilray Brands, Inc.
Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20…
TMC
freshTMC the metals company Inc.
The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is…
TSHA
freshTaysha Gene Therapies, Inc.
Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…
TVTX
freshTravere Therapeutics, Inc.
FILSPARI's dual-indication ramp has fully re-rated the equity: at ~$56.71 (2026-07-17) TVTX trades at consensus PT ($52–58) and 4% under its 2026-06-25 ATH close of $59.03, having gone sideways for four weeks. The approval binary is spent;…
UI
freshUbiquiti Inc.
Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,…
ULCC
freshFrontier Group Holdings, Inc.
Oil-tailwind leg inverted: Brent closed 88.09 on 2026-07-17 (+14% on the week on US-Iran supply fears), erasing the sub-$80 condition that drove the June double. Price is ~26% off the 8.41 high set one day before Citi's $9 target, a 10%…
USO
United States Oil Fund, LP
Late-June Iran/Hormuz flare-up flipped to a standdown Saudi supertankers now exiting Hormuz at post-truce highs (2026-07-02) and Trump says Iran 'agreed to just about everything.' USO is long the exact risk premium a signed Islamabad MoU…
VECO
Veeco Instruments Inc.
Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes passed 2026-02-06, only China SAMR remains (outside date 2026-09-30). Upside is ratio-capped and the live binary is the SAMR sign-off which has run slow and may move…
VIR
freshVir Biotechnology, Inc.
June's volume-backed reclaim to $10.03 failed to extend $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…
VKTX
Viking Therapeutics, Inc.
Last large independent obesity asset and standing M&A target, but VK2735's VANQUISH pivotal topline isn't until 2027 a catalyst vacuum into a maturing, crowded GLP-1 theme, bridged only by a secondary 3Q26 maintenance-dose readout. Stock…
VRNS
Varonis Systems, Inc.
Special-situation M&A: Bloomberg (2026-06-23) reported Varonis weighing a sale on PE interest (Blackstone/Thoma Bravo/Vista); shares ran ~$33→$42 on deal optionality atop accelerating SaaS ARR (+69% YoY Q1). Now a takeover-premium bet into…
VSH
freshVishay Intertechnology, Inc.
Cycle-turn re-rate is round-tripping: down 36.4% in a month and 45.6% off $69.47, now below the $50 placement price from the 2026-06-30 dilution. Q1's 1.34 book-to-bill was real but is fully paid for at 35x forward. Structure broken,…
VSTM
Verastem, Inc.
Two-engine KRAS oncology name: the first-approved LGSOC drug (AVMAPKI FAKZYNJA) funds the real swing oral KRAS G12D inhibitor VS-7375 in PDAC/CRC/NSCLC. Sector theme accelerating but the tape is dormant at $5.53 vs $14–18 targets; the…
WGS
GeneDx Holdings Corp.
Busted-growth genomics name recovering off the −49% May guide-cut crash ($170→$32); sell-side ratcheting targets back up (Guggenheim $74 Jun 29, Piper $63 Jun 23), but the ~early-Aug Q2 ARR print vs the ~$3,300 baseline is the binary. A…
WING
Wingstop Inc.
First annual same-store-sales decline in 22 years (Q1 2026 domestic SSS -8.7%) broke the compounder narrative; a ~50% relief bounce off the $116 low now runs into the July 29 Q2 print the binary on the guided H2 return to positive comps.…
XENE
Xenon Pharmaceuticals Inc.
X-TOLE2 Phase 3 win (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already de-risked azetukalner and re-rated XENE from the $40s to ~$71; the story is now maturing and range-bound into a procedural Q3 2026 NDA, with the next true binary…
YSS
freshYork Space Systems Inc.
Roll-up thesis has broken. Both acquisitions closed on schedule (ALL.SPACE 2026-07-08, $300M; Solestial ~$67M) yet YSS closed $17.93 on 2026-07-17 ~45% below the January IPO range and 4.6% off the $16.93 52-week low. Wolfpack's claim that…
ZBIO
Zenas BioPharma, Inc.
Phase-3-positive, NEJM-published B-cell modulator obexelimab (56% IgG4-RD flare cut) with a BLA filed Q2 2026 into a no-approved-therapy indication a first-in-disease setup. But the marquee de-risking catalyst already fired and the stock…
ZURA
Zura Bio Limited
IL-17/BAFF bispecific (tibulizumab) ran on a 2026-06-29 enrollment beat in HS and SSc, but that's execution de-risking, not efficacy the real binary is Q4 2026 TibuSHIELD topline. The RSI mid-80s spike faded ~8% into July with no hard…